Skip to content

Delix Therapeutics — Non-hallucinogenic psychedelic drugs for mental health

Recently funded· $100M Series C· November 9, 2026

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

Get it by email

Companies like Delix Therapeutics go out every weekday morning. One-click unsubscribe.

Agent? Subscribe over MCP

Round
$100M Series C
Investors
SV Health neurodegen fund, Strategic Pharma
Sectors
Biotechnology, Data and analytics, Healthcare, Science and engineering
Logged
November 9, 2026, in issue #70

Delix Therapeutics went out in issue #70, with 7 other picks.